What is VivoSense?
Since its inception in 2010, VivoSense has been at the forefront of innovation in the pharmaceutical clinical trial industry. The company leverages its proprietary VivoSense® software to analyze and interpret data from wearable sensors, aiming to enhance patient research and care. VivoSense is developing novel digital biomarkers to advance patient-focused drug development and precision medicine across various therapeutic indications, including cancer, Alzheimer's, and rare diseases. Its platform facilitates rigorous interpretation of subtle physiological shifts through customized, body-worn monitoring and analysis solutions, all rooted in scientific foundations. The company's mission is to harness the potential of real-world data at scale for regulatory and medical decision-making, accelerating the delivery of life-saving treatments.
How much funding has VivoSense raised?
VivoSense has raised a total of $25.1M across 2 funding rounds:
Debt
$150K
Series A
$25M
Debt (2020): $150K with participation from PPP
Series A (2022): $25M led by Perceptive Xontogeny Venture Fund and Debiopharm
Key Investors in VivoSense
Debiopharm
Debiopharm Investment is the investment division of Debiopharm Group, focused on safeguarding capital and generating financial returns. It encompasses departments for finance, real estate, and private equity.
Perceptive Xontogeny Venture Fund
Perceptive Xontogeny Venture Fund is likely a venture capital firm specializing in investments within the healthcare and biotechnology sectors, given its name.
PPP
Public-Private Partnership
What's next for VivoSense?
The recent major strategic investment signals a pivotal growth phase for VivoSense, likely enabling the company to scale its operations and further develop its digital biomarker platform. This significant backing, alongside its previous funding, positions VivoSense to deepen its impact within the pharmaceutical clinical trial sector. The company is poised to expand its reach in precision medicine and patient-focused drug development, leveraging real-world data to drive regulatory and medical advancements.
See full VivoSense company page
